Tairx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
April 20, 2021 at 10:56 pm IST
Share
TaiRx, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 3.359 million compared to TWD 3.156 million a year ago. Operating loss was TWD 163.022 million compared to TWD 223.246 million a year ago. Net loss was TWD 159.386 million compared to TWD 217.765 million a year ago. Basic loss per share from continuing operations was TWD 2.41 compared to TWD 3.66 a year ago.
TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.